It is evolutionarily certain that we will have more outbreaks, more pandemics, and frankly, they could be significantly worse ...

Winston Timp, the principal investigator of the Timp Lab and associate professor of Biomedical Engineering (BME) at the ...

A well-crafted narrative helps investors see not just the molecule in front of them, but the broader therapeutic and ...

Editor’s Note: This deep dive was originally published Sept. 24, 2025, as a special edition of Biopharm Executive. Subscribe ...

Commentary: Biotechnology lets scientists engineer natural ingredients into products, often more sustainably than if they were farmed. Here's what to know. Deenie is a CNET Perspectives contributor ...

Federal regulators are trying to make it easier to develop cheaper alternatives to powerful drugs that many Americans depend ...

The U.S. Food and Drug Administration is preparing to accelerate approvals for biosimilars, or generic versions of complex ...

Synthetic biology is ready for the next developmental milestone and America’s leadership depends on getting the financing right.

This analysis reviews the history and current status of biosimilar regulation in the US, concluding that changing the FDA’s interchangeability standards—as proposed by some policy makers—is a ...

There must be something about the human brain that’s different from the brains of other animals — something that enables humans to plan, imagine the future, solve crossword puzzles, tell sarcastic ...